MDxHealth (MDXH) director Siegel holds options for 10,000 ordinary shares
Rhea-AI Filing Summary
MDxHealth SA director Sanford Jay Siegel filed an initial ownership report showing compensation-related options, not a market trade. He holds options to purchase 10,000 ordinary shares at $2.18 per share, granted on June 27, 2025, vesting in full at the next-year annual general shareholders' meeting and expiring on June 27, 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Siegel Sanford Jay
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option | -- | -- | -- |
Holdings After Transaction:
Share Option — 10,000 shares (Direct)
Footnotes (1)
- F1. Represents options to purchase 10,000 ordinary shares of the Issuer at a price per share of $2.18 granted on June 27, 2025 which vest in full on the date of the annual general shareholders' meeting that takes place in the calendar year following the calendar year in which the options were granted.
Key Figures
Option grant size: 10,000 shares
Exercise price: $2.18 per share
Option expiration: June 27, 2035
+1 more
4 metrics
Option grant size
10,000 shares
Underlying ordinary shares for director options
Exercise price
$2.18 per share
Strike price of director share options
Option expiration
June 27, 2035
Expiration date of share options
Shares underlying options after filing
10,000 shares
Total underlying ordinary shares following report
Key Terms
Share Option, Ordinary Shares, annual general shareholders' meeting
3 terms
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does MDxHealth (MDXH) director Sanford Siegel report on this Form 3?
Sanford Siegel reports holding options to buy 10,000 MDxHealth ordinary shares at $2.18 per share. These options are a compensation award, not an open-market trade, and represent his initial disclosed derivative position as a company director.
When do Sanford Siegel’s MDxHealth (MDXH) options vest and expire?
The options vest in full on the date of the annual general shareholders’ meeting held in the calendar year after grant. They were granted June 27, 2025 and expire June 27, 2035, giving a long-term incentive horizon through that expiration date.